NDATOPICALCREAMPriority Review
Approved
Aug 1971
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 1w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HALOTEX (haloprogin) is a topical antifungal cream approved in 1971 for dermatological fungal infections. The mechanism of action and specific indications are not fully characterized in available data, but haloprogin historically was used for superficial mycotic infections. This is a legacy small-molecule product with over 50 years of market presence.
LOE Approaching
Approaching loss of exclusivity with moderate competitive pressure (30%) signals a contracting brand team focused on retention and generic transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings indicate minimal active hiring for HALOTEX; this is a wind-down product with limited career advancement opportunity. Employment on this brand is likely limited to legacy team members managing transition and eventual discontinuation.
Brand ManagerField Sales Representative
Worked on HALOTEX at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.